Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...

Results showed 92.9% of mirikizumab-treated patients who were in clinical remission at 1 year maintained clinical remission at 2 years. Continuous treatment with mirikizumab was associated with ...

Interim findings showed, the estimated mean annualized bleeding rate for treated bleeds was 0.53, with a median ABR of 0. Topline results were announced from a phase 3 trial evaluating Mim8 in ...

The researchers found that 69,213,936 prescriptions for OMDs were dispensed in the United States during the study period, (HealthDay News) — Prescriptions of obesity management drugs (OMDs) have ...

HealthDay News — The US Food and Drug Administration (FDA) has approved the first-ever clinical trials testing pig kidney transplants in people with kidney failure, marking a major step forward in ...

Ozempic (semaglutide) Glucagon-like peptide-1 receptor agonist To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in ...

A higher risk for ischemic heart diseases was associated with IBD only in male patients, whereas a negative association was seen among female patients. HealthDay News — Male patients with ...

Elevated LDL cholesterol, total cholesterol, triglycerides linked to reduced risk for glaucoma. HealthDay News — Elevated high-density lipoprotein cholesterol (HDL-C) is associated with an ...

The 2023 match saw a significant number of unfilled programs; of 115 programs, 35 failed to fill all positions. HealthDay News — The number of anesthesiology residents applying to pain medicine ...

BR55 was safe and highly accurate (>95%) at marking VEGFR2 expression in patients with breast, ovarian and thyroid cancer, as well as Crohn disease. The Food and Drug Administration (FDA) has ...

FDA issued a safety communication regarding the potential for missed alerts with diabetes devices due to software or hardware changes; a wearable continuous apomorphine infusion device has been ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.